Brain tumors are one of the most aggressive and detrimental forms of cancer. Approximately 210,000 cases of primary and metastatic brain tumors are estimated to be diagnosed each year in the United States (American Brain Tumor Association, 2012; National Brain Tumor Society, 2012). Indeed, brain tumors are the most common of the solid tumors in children and the second leading cause of cancer-related deaths in children under the age of 20. Although the exact cause of brain tumors is still unknown, several risk factors such as certain genetic disorders, environmental factors, and electromagnetic fi elds have been identifi ed (Chandana et al., 2008) . Treatment options for brain tumors are selected based on a number of different factors including tumor type, location and size of tumor, tumor grade, and age and general health of the patient. It is Radiation therapy, the most commonly used for the treatment of brain tumors, has been shown to be of major signifi cance in tumor control and survival rate of brain tumor patients. About 200,000 patients with brain tumor are treated with either partial large fi eld or whole brain radiation every year in the United States. The use of radiation therapy for treatment of brain tumors, however, may lead to devastating functional defi cits in brain several months to years after treatment. In particular, whole brain radiation therapy results in a signifi cant reduction in learning and memory in brain tumor patients as long-term consequences of treatment. Although a number of in vitro and in vivo studies have demonstrated the pathogenesis of radiation-mediated brain injury, the cellular and molecular mechanisms by which radiation induces damage to normal tissue in brain remain largely unknown. Therefore, this review focuses on the pathophysiological mechanisms of whole brain radiation-induced cognitive impairment and the identifi cation of novel therapeutic targets. Specifi cally, we review the current knowledge about the effects of whole brain radiation on pro-oxidative and pro-infl ammatory pathways, matrix metalloproteinases (MMPs)/tissue inhibitors of metalloproteinases (TIMPs) system and extracellular matrix (ECM), and physiological angiogenesis in brain. These studies may provide a foundation for defi ning a new cellular and molecular basis related to the etiology of cognitive impairment that occurs among patients in response to whole brain radiation therapy. It may also lead to new opportunities for therapeutic interventions for brain tumor patients who are undergoing whole brain radiation therapy. 
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• Risk of secondary malignancy Sheline et al. (1980) , New (2001) , Denham and Hauer-Jensen (2002) , , Béhin and Delattre (2004) , Moulder and Cohen (2007) ing, diarrhea, and hair loss. In addition, the presence of bloodbrain barrier (BBB) has been identifi ed as a major obstacle for chemotherapeutic treatment of brain tumors. While many efforts have been made to administer chemotherapy to brain tumors that circumvent the BBB in order to improve delivery of drugs, chemotherapy might not be suggested as an effective treatment method for brain tumors (Buckner et al., 2007; American Brain Tumor Association, 2012) . Radiation therapy has been commonly used as the standard treatment for brain tumors (Tsao et al., 2005; Khuntia et al., 2006; Kantor et al., 2008) . It employs controlled high energy rays such as x-ray and γ-ray to either kill cancer cells directly or interfere with their ability to grow. Radiation can be given by either external or internal means; external radiotherapy is a critical component to treat brain tumors in many patients (Buckner et al., 2007) . For example, stereotactic radiosurgery delivers a high dose of radiation during a single session from an external source, such as gamma knife and linear accelerator (LINAC), to treat brain tumors. Whole brain radiation therapy is another way of providing external radiation and is commonly used to treat various brain tumors by administering ionizing radiation to the entire brain. Whole brain radiation therapy may be given before, during, or after chemotherapy, or following partial or complete surgical removal of brain tumors. In addition, whole brain radiation therapy can be used to treat inoperable brain tumors and metastatic tuthe brain, it may not be effi cient for all malignant brain tumors. Deeply-seated tumors within the brain that are not accessible or tumors locating near critical or sensitive areas in the brain that control language, movement, vision, or other important functions cannot be surgically removed because of the excessive risk of neurological damage during the operation. Both general and specifi c risks to brain tumor surgery depend greatly on the extent of the procedure and include infection, bleeding, formation of blood clots, blood pressure instability, temporary or permanent neurological defi cits, coma, and death (Cohadon, 1990; American Brain Tumor Association, 2012) .
Chemotherapy uses one or more type of drug(s) to kill cancer cells. Even though chemotherapy alone gives mild advantage to treat brain tumors, it usually provides an adjuvant outcome in combination with surgery and radiation therapy. In fact, the survival benefi t in the patients with high-grade gliomas was observed when they were treated with a combination of chemotherapy and radiation therapy (Hegi et al., 2005; Stupp et al., 2005) . Although there have been great improvements in the development of chemotherapeutic agents for the treatment of brain tumors, the clinical applications of currently available drugs for brain tumors are very limited due to signifi cant side effects and insuffi cient delivery. The common clinical side effects of chemotherapy for brain tumors include suppression of the immune system, fatigue, bruises, bleeding, nausea, vomit-www.biomolther.org mors that have spread to the brain from other part of the body. Walker et al. (1979) suggested dose-dependent effects of radiation on malignant gliomas by demonstrating the relationship between increased radiation therapy dose and increased survival. Other clinical trials demonstrated that post-operative radiation therapy provides signifi cant survival benefi ts compared with surgery alone or chemotherapy (Andersen, 1978; Walker et al., 1978) . Additionally, recent advances in neuroimaging technologies with three-dimensional computerized treatment planning system and three-dimensional conformal radiotherapy (3D-CRT) have markedly enhanced effi cacy and safety of radiation therapy (Bucci et al., 2005) . Therefore, radiation therapy has been shown to be of major signifi cance in tumor control and survival rate of brain tumor patients (Sheline et al., 1980) . According to the Central Brain Tumor Registry of the United States (CBTRUS), about 200,000 patients with brain tumors are treated with either partial large-fi eld or whole brain radiation every year in the United States (Stone et al., 2004; Moulder and Cohen, 2007) .
RADIATION THERAPY AND BRAIN INJURY
The use of radiation therapy for treatment of brain tumors is limited by the risk of radiation-induced damage to the normal, healthy brain tissue that can subsequently lead to devastating functional defi cits (Sheline et al., 1980; New, 2001; Denham and Hauer-Jensen, 2002; Béhin and Delattre, 2004; Moulder and Cohen, 2007) . Radiation-induced brain injury is classifi ed as acute, early delayed (subacute), and late delayed reactions based on the timing of onset of symptoms (Tofi lon and Fike, 2000; Kim et al., 2008; Ramanan et al., 2010) . Acute injury, occurring 48 hours to weeks after whole brain radiation therapy, is fairly mild to moderate in severity and is involved in fatigue, hair loss, skin erythema, headache, nausea, drowsiness, and emesis. Early delayed (subacute) injury is observed 1 to 6 months after whole brain radiation therapy and is associated with the clinical symptoms of fatigue, somnolence, short-term memory loss, and transient demyelination. Even though acute and early delayed injuries can lead to severe medical conditions, it is generally believed that most of the symptoms and signs of these injuries are reversible. On the other hand, late delayed injury, occurring 6 months to several years after whole brain radiation therapy, is considered irreversible and progressive and is characterized by demyelination, vascular abnormalities, and ultimate white matter necrosis (Schultheiss and Stephens, 1992) .
Previous studies have demonstrated that late delayed injury is largely responsible for cognitive impairment (DeAngelis et al., 1989; Roman and Sperduto, 1995; Akiyama et al., 2001; Johannesen et al., 2003; Bentzen, 2006; Shi et al., 2006; Welzel et al., 2008; Douw et al., 2009; . Indeed, progressive impairments in learning and memory were observed in 40-50% of brain tumor patients as long-term consequences of radiation therapy. Recent randomized, prospective human clinical trials also provide evidence that the addition of whole brain radiation to stereotactic radiosurgery may cause a signifi cant reduction in learning and memory in patients with brain tumors (Chang et al., 2009) . Consistent with the human studies, a signifi cant deterioration of memory function was observed in aged rats over a 7-month period post-radiation therapy (Lamproglou et al., 1995) . Yoneoka et al. (1999) found a similar, late onset of cognitive impairment in adult rats at 12 months following cranial irradiation. Additionally, a fractionated dose of γ-ray irradiation to rats resulted in a signifi cant increase in working memory errors primarily at 6 and 9 months . Moreover, it was found that a clinically relevant regimen of fractionated whole brain radiation led to signifi cant impairments in spatial learning and reference memory in rats (Shi et al., 2006) . Furthermore, our most recent study demonstrated that a clinical fractionated series of whole brain radiation induces a transient defi cit in contextual learning, disruption of working memory, and progressive impairment of special learning in mice . In addition to cognitive impairment, whole brain radiation causes other brain injuries including growth hormone defi ciency and motor dysfunction (Table  2 ) (Darzy et al., 2005; Manda et al., 2007; Sara et al., 2011; Quik et al., 2012) . Although there have been signifi cant developments in understanding pathophysiological mechanisms as summarized in Table 3 , limited information on the etiology of radiation-induced damage to normal brain tissue is currently available. In particular, the cellular and molecular mechanisms responsible for whole brain radiation therapy-mediated cognitive impairment remain largely unknown. At present, there are no successful treatments or effective preventive strategies for radiation-induced brain injury. Therefore, the present review specifi cally focuses on three pathophysiological mechanisms by which whole brain radiation induces cognitive impairments;
(1) effects of radiation therapy on oxidative stress and infl ammation in brain, (2) effects of radiation therapy on matrix metalloproteinases and extracellular matrix in brain, and (3) effects of radiation therapy on physiological angiogenesis in brain. It will help identify therapeutic targets for novel preventive and treatment approaches for brain tumor patients who suffer from signifi cant side effects after whole brain radiation therapy.
Radiation therapy and infl ammation in brain
The pro-oxidative and pro-infl ammatory environments have been implicated in the pathophysiological process of brain injury and subsequent development of various neurodegenerative diseases (McGeer and McGeer, 1995; Dheen et al., 2007) . Indeed, oxidative stress can induce expression of proinfl ammatory mediators, such as cytokines, chemokines, and adhesion molecules, via redox-responsive transcription factor-mediated molecular signaling pathways. It is well known that expression of pro-infl ammatory genes is up-regulated by increased oxidative stress through activation of a variety of transcription factors, such as activator protein-1 (AP-1), nuclear factor-κB (NF-κB), cAMP responsive element-binding protein (CREB), specifi city protein-1 (SP-1), and signal transducers and activators of transcription (STATs) (Wung et al., 1997; Verhasselt et al., 1998; Lakshminarayanan et al., 1998; Simon et al., 1998; Bouloumie et al., 1999; Grösch and Kaina, 1999; Park et al., 2001; Lee et al., 2001a; Lee et al., 2001b; Lee et al., 2001c; Lee et al., 2001d; Flora et al., 2002; Lee et al., 2003; Lee et al., 2010b) .
Evidence suggests that oxidative stress-mediated overexpression of pro-infl ammatory mediators is associated with brain microvascular endothelial cell dysfunction and BBB Table 3 www.biomolther.org disruption leading to the initiation and progression of neurodegenerative diseases. For example, amyloid β (Aβ) peptides contribute to pathogenesis in Alzheimer's disease (AD) through pro-oxidative and pro-infl ammatory mechanisms. Previous studies have shown that Aβ-induced oxidative stress in brain can lead to an infl ammatory cascade via secretion of interferon-γ (IFN-γ) and interleukin-1β (IL-1β), as well as expression of CD40 in human brain microvascular endothelial cells (Suo et al., 1998; Akiyama et al., 2000) . It was also demonstrated that Aβ increases the ability of monocytes/macrophages to infi ltrate into brain tissue across the BBB (Fiala et al., 1998; Giri et al., 2002) . Additionally, oxidative stress and infl ammation in brain have been suggested to actively participate in the neurodegenerative process of Parkinson's disease (PD) (McGeer et al., 2001; Schulz and Falkenburger, 2004) . Degeneration of nigral dopaminergic neurons was observed in both an infl ammation-mediated rat model and an in vitro cell culture model of PD (Liu and Hong, 2003) . It was also found that cyclooxygenase-2 (COX-2) expression was induced specifi cally within the substantia nigra pars compacta (SNpc) dopaminergic neurons in human postmortem PD specimens and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD during the destruction of the nigrostriatal pathway (Teismann et al., 2003) . Furthermore, treatment with antioxidant compounds or non-steroidal anti-infl ammatory drugs (NSAIDs) exhibited benefi cial effects such as delaying the onset or slowing the progression of neurodegenerative diseases including AD and PD (McGeer and McGeer, 1995; Akiyama et al., 2000) . These fi ndings provide compelling evidence that oxidative stress-mediated infl ammatory responses in brain play a signifi cant role in the pathogenesis of neurological disorders. Recent evidence has identifi ed oxidative stress and infl ammation as important pathways leading to radiation-induced brain injury (Hong et al., 1995; Olschowka et al., 1997; Chiang et al., 1997; Kim et al., 2002; Denham and Hauer-Jensen, 2002; Gaber et al., 2003; Baluna et al., 2006) . For example, a marked elevation of COX-1/-2 activity and subsequent production of prostaglandin E 2 (PGE 2 ) synthesis in brain following ionizing radiation augments central nervous system (CNS) infl ammation through up-regulation of a variety of proinfl ammatory mediators including tumor necrosis factor-α (TNF-α), IL-1β, IL-6, inducible nitric oxide synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), and matrix metalloproteinase-9 (MMP-9) (Kyrkanides et al., 2002; Moore et al., 2005) . Enhanced expression of adhesion molecules, such as ICAM-1, vascular cell adhesion molecule-1 (VCAM-1) and Eselectin, was also observed in irradiated brains (Hong et al., 1995; Olschowka et al., 1997; Gaber et al., 2003; Baluna et al., 2006) .
Radiation has been reported to up-regulate expression of pro-infl ammatory cytokines and chemokines in brain. A rapid induction of gene expressions of the pro-infl ammatory cytokines, such as TNF-α and IL-1β, in response to radiation has been implicated in radiotherapy-associated damages to the brain (Hong et al., 1995; Gaber et al., 2003) . Moreover, a signifi cant and marked up-regulation of mRNA and protein expression of pro-infl ammatory mediators, including TNF-α, IL-1β, and monocyte chemoattractant protein-1 (MCP-1), was observed in hippocampal and cortical regions isolated from irradiated brains. Interestingly, cytokine expression was regionally specifi c since TNF-α levels were signifi cantly elevated in cortex compared to hippocampus and IL-1β levels were elevated in hippocampus compared to cortical samples. A series of electrophoretic mobility shift assays (EMSA) also demonstrated that whole brain radiation signifi cantly increased activation of pro-oxidative and pro-infl ammatory transcription factors including AP-1, NF-κB, and CREB. (Raju et al., 2000; Lee et al., 2010b) . Furthermore, both in vitro and in vivo studies showed that whole brain radiation-induced pro-infl ammatory environments in the brain may be, at least in part, mediated through activation of microglia, suggesting the potential contribution of specifi c type of cells to the overexpression of proinfl ammatory mediators in the brain after radiation (Lee et al., 2010b; Conner et al., 2011) . These data provide robust evidence indicating that oxidative stress-mediated infl ammation is one of the major consequences of whole brain radiation and plays a pivotal role in subsequent radiation-induced tissue injury to normal brain. These studies may contribute to a deeper understanding of the pathophysiological mechanisms responsible for radiation-induced brain injury at the cellular and molecular levels. More importantly, it may provide a foundation for the development of novel strategies for prevention and treatment of radiation-induced brain injury specifi cally targeted against pro-oxidative and pro-infl ammatory pathways.
In contrast, acute immune responses in cancer patients undergoing radiation therapy may have positive effects. Sepah and Bower (2009) detected higher levels of pro-infl ammatory cytokines, such as IL-1β and IL-6, in early-stage breast and prostate cancer patients after radiation treatment, suggesting that the acute infl ammatory responses may facilitate normal tissue repair processes. It is well known that aging is an important prognostic factor in determining the response of brain tumors to radiation therapy (Flowers, 2000; Schindler et al., 2008) . Clinical studies have shown that the use of radiation therapy for treatment of malignant gliomas resulted in significantly lower survival rates for patients older than 70 years of age compared with those for patients aged 70 and younger (Peschel et al., 1993; Villà et al., 1998) . In addition, patients aged 50 or under survived longer than patients over 50 after radiation therapy due to inherent differences in the sensitivity of clonogenic cells to radiation (Rosenblum et al., 1982) . These studies clearly indicate that aging exerts a profound effect on the effi cacy of radiation therapy for treatment of brain tumors. Although it is generally believed that the immune responses and the effectiveness of radiation therapy decline with age, the association among aging, infl ammation, and radiation therapy remains to be further investigated. Our recent data demonstrated that radiation-induced acute infl ammatory responses, such as overexpression of pro-infl ammatory cytokines (e.g., TNF-α, IL-1β, and IL-6), adhesion molecules (e.g., ICAM-1, VCAM-1, and E-selectin), chemokine (e.g., MCP-1), and matrix metalloproteinases (e.g., MMP-9), were signifi cantly impaired in aged brain (Lee et al., 2010a) . The impaired response to whole brain radiation with age appears to reveal a generalized attenuation of the cellular response to damage and a reduced capacity of aging tissues to induce essential repair systems necessary for cellular maintenance. Additionally, these data contribute to a better understanding of age-dependent changes in radiation-mediated immune and infl ammatory responses in brain and may lead to the development of effective treatment strategies for brain tumor patients who are undergoing radiation therapy.
Since the induction of both pro-oxidative and pro-infl amma-tory pathways in brain plays crucial roles in the pathophysiological mechanisms of radiation-mediated brain injury, therapies selectively targeting these pathways have shown great potentials in protecting the brain from damages (Table 4) . Indeed, a variety of therapeutics with antioxidant activity has been identifi ed as radioprotectors against brain injury. Human clinical study revealed signifi cant improvements in global cognitive ability, memory, and executive function among patients with nasopharyngeal carcinoma who received α-tocopherol, the most biologically active form of vitamin E and a fat-soluble antioxidant, for 1 year after radiation therapy (Chan et al., 2004) . Pre-treatment with α-lipoic acid, a widely available over-the-counter nutritional supplement in the United States, prior to whole body x-ray irradiation resulted in a signifi cant neuroprotection by attenuating oxidative stress in cerebellum and recovering cognitive dysfunction in irradiated mice (Manda et al., 2007) . Additionally, radioprotective actions of melatonin (N-acetyl-5-methoxytryptamine), a naturally occurring hormone with powerful antioxidant property, have demonstrated the potential clinical use for prevention of oxidative stress-mediated brain damage induced by ionizing radiation (Erol et al., 2004; Undeger et al., 2004; Shirazi et al., 2007) . Recent study also showed that pre-administration of the methanol extract of Vernonia amygdalina leaf, a well-known for its antioxidant activity, signifi cantly mitigated the radiation-induced gross morphometry changes in rat brain, such as reduction of the relative weight of the whole brain, relative weight of the cerebellum, the maximum width, rostrocaudal dimension, and dorsoventral extent of the cerebellum (Owoeye et al., 2011) . In addition to antioxidants, anti-infl ammatory approaches have been employed as therapeutic strategies to radiation-induced brain injury. Monje et al. (2003) showed that infl ammatory blockade with indomethacin, one of the most common NSAIDs, restored the imapired neurogenesis caused by cranial irradiation. Administration of another anti-infl ammatory drug pioglitazone, a peroxisomal proliferator-activated receptor (PPAR) agonist, prior to, during, and up to 4-or 54-weeks after fractionated whole brain radaition signifi cantly recovered the radiationinduced cognitive impairment in rats (Zhao et al., 2007; Ramanan et al., 2010) . Moreover, treatment of rats with ramipril, one of the angiotensin-converting enzyme (ACE) inhibitors with anti-infl ammatory activity, signifi cantly ameriolated radiation-induced brain damage (Kim et al., 2004; Ryu et al., 2007; Jenrow et al., 2010) . Furthermore, chronic administration of atorvastatin, a member of drug class known as statins which have also shown to possess antioxidant and anti-infl ammatory properties (Kim et al., 2008) , and ramipril exhibited combined protective effects against radiation-induced impairment of hippocampal neurogenesis in rats (Jenrow et al., 2011) . These studies provide compelling evidence that pharmacological strategies designed to selectively target oxidative stress-and infl ammation-dependent pathways in brain could reduce radiation-induced damages to normal brain tissue.
Radiation therapy and extracellular matrix in brain
The BBB is a complex neuroprotective system consisting of brain microvascular endothelial cells, astrocytes, pericytes, and basement membrane (Rubin and Staddon, 1999) . It provides a highly selective barrier that tightly regulates the exchange of materials and cells between the circulation and brain tissue (Abbott et al., 2006) . Under physiological conditions, the BBB restricts and controls the movement of various chemical substances and macromolecules to maintain the brain homeostasis that is essential for the normal operation www.biomolther.org of the nervous system (Banerjee and Bhat, 2007) . In some cases, however, the BBB becomes disrupted or modifi ed as a consequence of various pathological insults (Banerjee and Bhat, 2007) . Indeed, alteration or disruption of the BBB is commonly found in patients with neurological disorders, such as stroke, traumatic brain injury (TBI), AD, PD, and HIV-1 dementia (Staddon et al., 1995; Rubin and Staddon, 1999; Toborek et al., 2005; Banerjee and Bhat, 2007) . Studies have shown that alterations in the BBB may be responsible for injury to the normal brain tissue after radiation therapy (Diserbo et al., 2002; Nordal and Wong, 2005) . For example, radiation mediates disruption of the BBB by damaging the structural and functional integrity of the microvasculature in brain (Baker and Krochak, 1989; Rubin et al., 1994) . In addition, Delattre et al. (1989) demonstrated that cranial irradiation (CRT) markedly increased regional capillary permeability and capillaries of normal brain tissue are more sensitive to the acute effects of CRT than capillaries found in brain tumors. It was also found that BBB permeability was signifi cantly increased in rat brain after whole brain and whole body irradiation (d 'Avella et al., 1992; Diserbo et al., 2002) . Furthermore, evidence from other in vivo studies has revealed a rapid increase in BBB breakdown in response to interstitial brachytherapy (Fike et al., 1985; Groothuis et al., 1987; Bernstein et al., 1990) . The cellular and molecular mechanisms by which radiation induces BBB disruption, however, remain unsolved.
The extracellular matrix (ECM) is a complex of various proteins and proteoglycans, including collagens, laminin, fi bronectin, and tenascin (Paulsson, 1992) . Besides acting as a physical barrier to the passage of macromolecules and cells, ECM separates adjacent tissues, provides mechanical support for cell attachment, and serves as a substratum for cell migration and a medium of communication between cells (Rutka et al., 1988; Paulsson, 1992; Tilling et al., 2002) . In particular, since ECM proteins are major molecular constituents of the basement membrane and maintain the integrity of the BBB, degradation and consequent rearrangement of ECM are critically involved in the breakdown of the BBB. For example, the injection of bacterial collagenase to rat brain resulted in degradation of ECM, disruption of basement membrane, and an increase in BBB permeability (Rosenberg et al., 1993) . In addition, an increased degradation of collagen type IV was found to be signifi cantly associated with BBB disruption in a rat model of bacterial meningitis ) and a mouse model of herpessimplex virus (HSV) encephalitis . Tilling et al. (1998) also reported that ECM constituents such as collagen type IV, fi bronectin, and laminin signifi cantly increased the transcellular electrical resistance of primary brain microvascular endothelial cells in an in vitro model of BBB, indicating that these proteins play an important role in enhancing barrier properties.
The matrix metalloproteinases (MMPs) are a large family of ECM-degrading enzymes and have been implicated in the pathophysiological processes of neurodegenerative diseases by causing BBB disruption (Mun-Bryce and Rosenberg, 1998; Romanic et al., 1998; Strup-Perrot et al., 2005) . Indeed, in a variety of physiological and pathological conditions, MMPs become activated and play a key role in degradation of the ECM proteins (Planas et al., 2001; Kim and Joh, 2012) . Depending on substrate specifi city and structural differences, MMPs are subdivided into gelatinases (MMP-2 and -9), collagenases (MMP-1, -8, -13, and -18), stromelysins (MMP-3, -10, and -11), matrilysins (MMP-7 and -26), metalloelastase (MMP-12), and membrane-type (MT) MMPs (Romanic et al., 1998; Visse and Nagase, 2003; StrupPerrot et al., 2005) . In particular, the gelatinases MMP-2 and MMP-9, the most commonly investigated MMPs in the CNS, are able to degrade ECM components including collagen type IV which is essential for maintaining BBB integrity (Kim and Joh, 2012) . The enzymatic activity of MMPs is regulated by tissue inhibitors of metalloproteinases (TIMPs), the endogenous inhibitors with a higher affi nity for specifi c MMPs (Aoudjit et al., 1999; Lukes et al., 1999) . For example, TIMP-1 inhibits MMP-9 activity by forming a specifi c complex with MMP-9, whereas MMP-2 is bound by TIMP-2 (Aoudjit et al., 1999; Wang et al., 2000; Giannelli et al., 2002; . Therefore, a favorable balance of MMPs/TIMPs system plays a pivotal role in maintaining normal homeostasis in the CNS which is essential for preventing neurological disorders (Gardner and Ghorpade, 2003; Kim and Joh, 2012) .
Evidence from in vivo and in vitro studies has demonstrated that MMPs and TIMPs are associated with radiation-induced damage to various tissues. For example, the overexpression of MMP-2 and MMP-9 was observed in lung after thoracic irradiation (Yang et al., 2006; Yang et al., 2007) . Araya et al. (2001) have reported that radiation causes a signifi cant elevation of MMP-2 production but no effect on TIMP-2 in human airway epithelial cells after irradiation, indicating the balance between MMP-2 and TIMP-2 was in favor of MMP-2 promoting proteolysis. Additionally, the use of pelvic radiation therapy for prostate cancer patients resulted in signifi cant increases in MMP-2 and MMP-9 activity in rectal mucosa (Hovdenak et al., 2002) . It was also found that abdominal irradiation led to a signifi cant elevation in MMP-2 and MMP-14 levels in rat ileum (Strup-Perrot et al., 2005) . Moreover, radiation-mediated upregulation of MMP-2 expression has been observed in various cell types, including astrocytes, endothelial cells, and epithelial cells (Sawaya et al., 1994; Nirmala et al., 2000; Zhao et al., 2004) . Furthermore, recent study provides evidence that whole brain radiation differentially regulates MMPs/TIMPs system in brain and an imbalance between MMP-2 activity and TIMP-2 expression may have an important role in the pathogenesis of radiation-induced brain injury by degrading ECM components of the BBB basement membrane . These fi ndings may contribute to defi ning a novel cellular and molecular basis for radiation-induced BBB disruption and subsequent brain injury that will lead to new opportunities for preventive and therapeutic interventions for brain tumor patients who are undergoing radiotherapy. Further studies, however, are necessary to elucidate the exact mechanistic links among MMPs/TIMPs system, ECM degradation, and BBB disruption in brain after whole brain radiation therapy.
Based on previous studies related to the pivotal role of ECM in normal homeostasis in brain, strategies aimed at blocking ECM degradation or modulating MMPs/TIMPs system in brain may be attractive for preventing and/or attenuating radiationinduced brain injury. One potential experimental approach is to administer a series of pharmacological agents that selectively inhibit MMPs by different mechanisms of action, including minocycline, simvastatin, AG3340, DPC-A37668, GM6001, PD166793, and Ro-31-9790 (Barnett et al., 2007; Garcia-Alloza et al., 2009; Krishnamurthy et al., 2009) , to animal models of whole brain radiation therapy which can lead to identifi cation of novel drugs for prevention and/or treatment for radiation-induced brain injury. However, there are no reports demonstrating therapeutic approaches targeting ECM or MMPs/TIMPs system in irradiated brain.
Radiation therapy and physiological angiogenesis in brain
Angiogenesis is the process of developing new blood vessels from pre-existing vessels. It has been known to play critical roles not only in many physiological processes such as embryonic development and wound healing, but also in the development of a number of pathological conditions including progression of tumors. These events are characterized by the dynamic, temporally and spatially coordinated interactions among endothelial cells, angiogenic factors, and ECM proteins (Miller et al., 1994; Hanahan, 1997) . One of the most important and extensively studied angiogenic factors is vascular endothelial growth factor (VEGF) which has a potent and specifi c activity for the vascular endothelium (Ferrara, 1999; Ribatti, 2005; Tammela et al., 2005) . VEGF and its receptors serve to initiate endothelial cell proliferation, endothelial cell migration, and production of new capillary sprouts, which promote vasculogenesis and angiogenesis (Breier et al., 1992; Plate, 1999; Ferrara et al., 2003) . VEGF is also considered as a survival factor for endothelial cells by protecting them from apoptosis (Ferrara, 1999; Alavi et al., 2003) . In addition to VEGF, angiopoietins are a second family of vascular regulatory molecules that are also specifi c for the vascular endothelium involving in both physiological and pathological blood vessel generation (Davis et al., 1996) . Although angiopoietin-1 (Ang-1) is not directly associated with endothelial cell proliferation (Davis et al., 1996) , it mediates interactions between the endothelium and the surrounding matrix, which leads to stimulation of EC migration (Witzenbichler et al., 1998) , sprouting (Koblizek et al., 1998) , and tubule formation (Hayes et al., 1999) . Indeed, Ang-1 is necessary for subsequent vascular remodeling as well as vessel maturation and stabilization, while VEGF plays an active role during the early stages of vessel development (Sato et al., 1995) . All angiopoietin families, such as Ang-1, -2, -3, and -4, bind to the endothelial receptor tyrosine kinase (Tie-2) which is typically expressed by vascular endothelial cells (Peters et al., 2004) . The balance of Ang-1/Tie-2 system has been known to be necessary for vessel maturation and stabilization (Sato et al., 1995) . Ang-2 serves as a functional antagonist of Ang-1. By blocking Tie-2 signaling, Ang-2 leads to a loosening of tight vascular structure (Maisonpierre et al., 1997; Mandriota and Pepper, 1998; Yancopoulos et al., 2000) . This loosening of cell-matrix and cell-cell interactions allows the endothelial cells to become more sensitive and responsive toward the other angiogenic factors such as VEGF. For example, in the absence of the activating signal from VEGF, Ang-2 promotes endothelial cell death and subsequently leads to rarefaction of vessels. In the presence of high expression levels of VEGF, however, the process of physiological angiogenesis is facilitated by Ang-2 (Mandriota and Pepper, 1998; Yancopoulos et al., 2000) . These studies suggest that a dynamic interplay among angiogenic factors, such as Ang-1, Ang-2, Tie-2, and VEGF, plays a key role in regulating various aspects of physiological angiogenesis (Fig. 1) .
It is widely believed that radiation-mediated injury to normal tissues including brain is a consequence of acute and late damages to the microvascular endothelium (Dimitrievich et al., 1984; Baker and Krochak, 1989; Ljubimova et al., 1991; Roth et al., 1999; Nguyen et al., 2000) . Several studies have identifi ed microvascular networks as the most sensitive part in response to the radiation therapy and demonstrated the critical role of microvasculature in the pathogenesis of radiation-induced damages to normal tissues. For example, an increased permeability and an irregular proliferation of endothelial cells of microvasculature were observed in irradiated normal tissues (Baker and Krochak, 1989) . Results from early and late effects of ionizing radiation on the normal tissue microvascular networks showed adverse alterations in the structure and function of microvasculatures such as signifi cant decreases in vessel diameter and capillary surface area, a signifi cant increase in vessel hematocrit, and a signifi cant reduction of blood fl ow in locally irradiated hamster cremaster muscles (Roth et al., 1999; Nguyen et al., 2000) . A number of previous studeis also suggest that radiation-induced early and persistent damages to the microvasculature may be responsible for cerebral vessel rarefaction leading to brain injury including cognitive impairments. Brown et al. (2005) revealed that fractionated whole brain radiation, a clinically relevant regimen of radiation therapy for brain tumor patients, substantially decreased both vessel density and length in rat brains at 10 weeks post-irradiation. A signifi cant decrease in vessel density in rat brain with cognitive impairment was also observed from 10 weeks to 52 weeks after fractionated whole brain radiation, suggesting a potential role for loss of cerebral capillary in radiation-induced dementia . Recent studies further confi rmed the whole brain radiation-induced cerebral microvascular rarefaction and cognitive impairments (Warrington et al., 2011; Warrington et al., 2012) . It was also found that a single exposure of rat brain strongly decreased cerebral blood fl ow (CBF) at 12 and 18 months after radiation (Keyeux et al., 1997) .
Recent evidence has demonstrated that the reduction of the number of endothelial cells may be responsible for the radiation-induced decrease in vessel density in brain. For example, the local irradiation of the rat brain caused a progressive and dose-related depletion in endothelial cells in the choroid plexus (Calvo et al., 1987) . A dose-dependent decrease in endothelial cell number was also observed in rat brain within 24 hours and maintained for up to 1 month after irradiation (Ljubimova et al., 1991) . In addition, Lyubimova and Hopewell (2004) observed the time-dependent changes in endothelial cell number in rat brain for up to 65 weeks after irradiation. The initial marked loss of endothelial cells and the subsequent slow decline in endothelial cell density were detected at 24 hours and between 26 and 52 weeks after irradiation, respectively. These studies clearly indicate that cerebrovascular endothelial cells are the primary target cell population in the radiationinduced brain injury. Moreover, a radiation-mediated doseand time-dependent induction of apoptosis of endothelial cells was observed in mouse central nervous system including spinal cord sections and multiple regions of the brain (medulla, pons, and hippocampus), suggesting that radiation-induced loss of endothelial cells in brain is mediated by apoptotic cell death (Peña et al., 2000) . Results from our recent study further confi rmed that whole brain radiation signifi cantly reduced endothelial cell density in brain by increasing endothelial cell apoptosis and decreasing endothelial cell proliferation . A signifi cant decrease in mRNA and protein expression of Ang-1, Tie-2, and VEGF was also detected in irradiated rat brains compared with sham-irradiated controls, while whole brain radiation signifi cantly up-regulated Ang-2 mRNA and protein expression . This study provides evidence for the fi rst time that radiation-mediated differential regulation of various angiogenic factors may be responsible for attenuating physiological angiogenesis resulting in vessel rarefaction in irradiated brain (Fig. 2) .
Although more detailed mechanisms of radiation-induced vessel rarefaction in brain remain to be further investigated, recovering cerebrovascular rarefaction by facilitating physiological angiogenesis in brain sounds a reasonable approach as therapeutic intervention strategy for treatment of radiation-induced brain injury (Table 4) . Warrington et al. (2011) assessed the effects of hypoxia as a potential mechanism to reverse the radiation-induced microvascular rarefaction and found out that chronic systemic hypoxia was capable of completely restoring cerebrovascular density in irradiated animal brain. More importantly, treatment of animals with systemic hypoxia completely reversed whole brain radiation-induced impairments in learning and memory . In addition, the radioprotective drug gammaphos (S-2[3-amino propylamino] ethylphosphorothioate) exerted protective effects on cerebrovascular system though effective prevention of endothelial cell loss in brain (Plotnikova et al., 1984; Plotnikova et al., 1988; Lyubimova and Hopewell, 2004) . It was also found that less than 10% of animals receiving gammaphos showed brain injury such as necrosis, while approximately 50% of the animals that had not received gammaphos exhibited brain injury by 65 weeks after irradiation (Lyubimova and Hopewell, 2004) .
CONCLUSIONS
Whole brain radiation therapy continues to be a main treatment modality in the therapeutic management of brain tumors. The clinical use of radiotherapy, however, has been limited by the risk of radiation-mediated damages to normal brain tissue that can eventually cause serious brain injury including cognitive impairment. At present, the cellular and molecular mechanisms related to the etiology of cognitive impairment that occurs among brain tumor patients in response to whole brain radiation therapy remain largely unknown. In this review, we described three pathophysiological mechanisms that whole brain radiation leads to cognitive impairment by (1) triggering induction of pro-oxidative and pro-infl ammatory environments in brain, (2) causing imbalance MMPs/TIMPs system and degradation of ECM in brain, and (3) alerting physiological angiogenesis through differential regulation of angiogenic factors in brain. These fi ndings may contribute to defi ning a cellular and molecular basis for radiation-induced cognitive impairment. It will also help identify therapeutic targets for novel preventive and/or treatment strategies for brain tumor patients who suffer from signifi cant clinical side effects after whole brain radiation therapy.
